MPR Weekly Dose Podcast
This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there's updates to the cancer drug Keytruda.
Safety Alerts and Recalls
A preliminary analysis of long-term follow-up data (up to 5 years) involving patients with peripheral arterial disease (PAD) treated with paclitaxel-coated products revealed a ‘potentially concerning’ signal of increased long-term mortality when compared with those treated with uncoated devices, according to the Food and Drug Administration (FDA). Among the 3 trials that included 5-year follow-up…
Studies into the long-term health impact of e-cigarettes - which usually contain nicotine - are limited but of the studies that have been completed, there have been mixed results.
The Carbon Monoxide Breath Sensor System (COBSS) informs the user how breath carbon monoxide levels are affected by their smoking behavior.
A recent survey found that a substantial number of clinicians believe e-cigarettes can help patients reduce or stop smoking, with 37.9% stating they having recommended e-cigarettes to patients who smoke.
New trial data may alleviate some concerns regarding the smoking cessation medications varenline, bupropion and nicotine patches and the risk of neuropsych events.
An analysis conducted by UC San Francisco (UCSF) researchers found that rather than aid smoking cessation, e- cigarette users were 28% less likely to quit smoking traditional cigarettes.
A single dose of psilocybin can alleviate negative moods in patients with life-threatening cancer, a new study has found.